Fulcrum Capital LLC Sells 44 Shares of Amgen Inc. (NASDAQ:AMGN)

Fulcrum Capital LLC cut its stake in Amgen Inc. (NASDAQ:AMGN) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,945 shares of the medical research company’s stock after selling 44 shares during the period. Fulcrum Capital LLC’s holdings in Amgen were worth $2,592,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AMGN. Capital Performance Advisors LLP bought a new position in shares of Amgen during the 3rd quarter worth approximately $25,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen during the 2nd quarter valued at $30,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the 3rd quarter valued at $29,000. Matrix Trust Co bought a new position in shares of Amgen during the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the 3rd quarter worth $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 2.7 %

Shares of AMGN traded up $7.08 during midday trading on Monday, hitting $269.31. 1,745,551 shares of the stock were exchanged, compared to its average volume of 2,855,401. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a fifty day simple moving average of $279.10 and a 200 day simple moving average of $308.66. The firm has a market cap of $144.76 billion, a P/E ratio of 34.48, a P/E/G ratio of 2.91 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the firm earned $4.96 earnings per share. On average, research analysts anticipate that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.53%. Amgen’s dividend payout ratio (DPR) is currently 121.90%.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Deutsche Bank Aktiengesellschaft cut their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. UBS Group reduced their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. TD Cowen lifted their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada dropped their target price on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Finally, Robert W. Baird reiterated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.